We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
STERIS' (STE) Improved Volume, New Buyouts Drive Growth
Read MoreHide Full Article
STERIS (STE - Free Report) is gaining from a strong rebound of procedure volumes in the United States, leading to solid growth in the Healthcare business. The stock carries a Zacks Rank #2 (Buy).
STERIS' Healthcare segment is gaining from the successful market adoption of its comprehensive offerings, including infection prevention consumables and capital equipment. Further, its services to maintain that equipment, repair reusable procedural instruments and outsource instrument reprocessing services are gaining traction. Continuous procedure volume growth in the United States and favorable pricing and market share gains are driving the segment’s organic growth.
On the capital equipment side, the easing of supply-chain issues and reduced lead times have contributed to strong shipments in the first quarter of fiscal 2024. The company’s robust capital spending shows that nearly 40% of first-quarter orders have been made toward large projects.
STERIS’ customers in the Applied Sterilization Technologies (AST) business are mostly the manufacturers of single-use, sterile technologies that are used in aseptic manufacturing of vaccines and biopharmaceuticals. Since the beginning of the third quarter of fiscal 2023, STERIS’ customers have been left stranded with a bulk of inventory, possibly caused by vaccine reluctance or vaccine production in general. As a consequence, the company’s volumes went down.
However, management is certain that the sector’s long-term growth will return once the short-term destocking of the inventory is worked through. This is further solidified by the fact that customers across this segment have made significant investments to expand their manufacturing capacity for long-term growth.
Shares of STERIS have improved 31.8% over the past year against the industry’s 1% decline.
On the flip side, challenging macroeconomic conditions in the form of supply chain constraints, higher material costs, ongoing labor inflation and lower productivity continue to weigh significantly on STERIS’ margins. In fiscal 2023, the company faced additional headwinds from inflation on raw materials. Supply chain disruptions are slowing down STERIS’ ability to ship capital equipment and higher interest rates may negatively impact interest expense.
Added to this, STERIS competes for pharmaceutical, research and industrial customers against several large companies that have robust product portfolios and global reach, as well as a number of small companies with limited product offerings and operations in one or a few countries. In the Healthcare segment, STERIS’ notable competitors include 3M, Baxter, Boston Scientific, Belimed, Ecolab, Getinge, Go Jo, Johnson & Johnson, Kimberly-Clark, Skytron and Stryker.
Cardinal Health stock has risen 31.1% in the past year. Earnings estimates for the company have increased from $6.65 to $6.66 in 2023 in the past 30 days and from $7.56 to $7.57 for 2024 in the past seven days.
CAH’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.03%. In the last reported quarter, it posted an earnings surprise of 4.73%.
Estimates for Haemonetics’ 2023 earnings per share have remained constant at $3.82 in the past 30 days. Shares of the company have increased 13.1% in the past year against the industry’s decline of 10.3%.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.39%. In the last reported quarter, it posted an earnings surprise of 38.16%.
Estimates for Align Technology’s 2023 earnings have moved up from $8.77 to $8.78 per share in the past 30 days. Shares of the company have increased 29.7% in the past year compared with the industry’s growth of 19.1%.
ALGN’s earnings beat estimates in three of the trailing four quarters and missed in one. In the last reported quarter, it posted an earnings surprise of 9.90%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
STERIS' (STE) Improved Volume, New Buyouts Drive Growth
STERIS (STE - Free Report) is gaining from a strong rebound of procedure volumes in the United States, leading to solid growth in the Healthcare business. The stock carries a Zacks Rank #2 (Buy).
STERIS' Healthcare segment is gaining from the successful market adoption of its comprehensive offerings, including infection prevention consumables and capital equipment. Further, its services to maintain that equipment, repair reusable procedural instruments and outsource instrument reprocessing services are gaining traction. Continuous procedure volume growth in the United States and favorable pricing and market share gains are driving the segment’s organic growth.
On the capital equipment side, the easing of supply-chain issues and reduced lead times have contributed to strong shipments in the first quarter of fiscal 2024. The company’s robust capital spending shows that nearly 40% of first-quarter orders have been made toward large projects.
STERIS’ customers in the Applied Sterilization Technologies (AST) business are mostly the manufacturers of single-use, sterile technologies that are used in aseptic manufacturing of vaccines and biopharmaceuticals. Since the beginning of the third quarter of fiscal 2023, STERIS’ customers have been left stranded with a bulk of inventory, possibly caused by vaccine reluctance or vaccine production in general. As a consequence, the company’s volumes went down.
STERIS plc Price
STERIS plc price | STERIS plc Quote
However, management is certain that the sector’s long-term growth will return once the short-term destocking of the inventory is worked through. This is further solidified by the fact that customers across this segment have made significant investments to expand their manufacturing capacity for long-term growth.
Shares of STERIS have improved 31.8% over the past year against the industry’s 1% decline.
On the flip side, challenging macroeconomic conditions in the form of supply chain constraints, higher material costs, ongoing labor inflation and lower productivity continue to weigh significantly on STERIS’ margins. In fiscal 2023, the company faced additional headwinds from inflation on raw materials. Supply chain disruptions are slowing down STERIS’ ability to ship capital equipment and higher interest rates may negatively impact interest expense.
Added to this, STERIS competes for pharmaceutical, research and industrial customers against several large companies that have robust product portfolios and global reach, as well as a number of small companies with limited product offerings and operations in one or a few countries. In the Healthcare segment, STERIS’ notable competitors include 3M, Baxter, Boston Scientific, Belimed, Ecolab, Getinge, Go Jo, Johnson & Johnson, Kimberly-Clark, Skytron and Stryker.
Other Key Picks
Some other top-ranked stocks in the broader medical space are Cardinal Health (CAH - Free Report) , Haemonetics (HAE - Free Report) and Align Technology (ALGN - Free Report) , each carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Cardinal Health stock has risen 31.1% in the past year. Earnings estimates for the company have increased from $6.65 to $6.66 in 2023 in the past 30 days and from $7.56 to $7.57 for 2024 in the past seven days.
CAH’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.03%. In the last reported quarter, it posted an earnings surprise of 4.73%.
Estimates for Haemonetics’ 2023 earnings per share have remained constant at $3.82 in the past 30 days. Shares of the company have increased 13.1% in the past year against the industry’s decline of 10.3%.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.39%. In the last reported quarter, it posted an earnings surprise of 38.16%.
Estimates for Align Technology’s 2023 earnings have moved up from $8.77 to $8.78 per share in the past 30 days. Shares of the company have increased 29.7% in the past year compared with the industry’s growth of 19.1%.
ALGN’s earnings beat estimates in three of the trailing four quarters and missed in one. In the last reported quarter, it posted an earnings surprise of 9.90%.